Weight-loss patients voice concerns as CVS Caremark drops Zepbound coverage for Wegovy, though exceptions may exist for those ...

A U.S. ban on copycat versions of Novo Nordisk's Wegovy has begun to lift use of the weight loss drug, but the company will ...

Some patients reluctantly shifted to save money while others have appealed for coverage of Zepbound after having experienced ...

The U.S. FDA ban on compounded versions of Novo Nordisk's Wegovy has increased its prescriptions by 33%. Despite this, ...

CVS Caremark will stop covering Eli Lilly’s Zepbound. Wegovy, the GLP-1 medication to treat obesity from Lilly competitor Novo Nordisk, will still be covered under plans managed by CVS Caremark.

Do those on Zepbound have to switch to Wegovy after Caremark drops Zepbound from preferred coverage? What options are there? Here's what to know.

Since the US Food and Drug Administration (FDA) implemented a ban on ‘compounded’ versions of Wegovy on 22 May, new ...

Experts say supplement companies have tried to capitalize on the GLP-1 craze, putting the phrase in their product names, ...

(Reuters) -Eli Lilly said on Sunday its drug Zepbound was superior to Novo Nordisk's Wegovy across five weight-loss targets such as reducing waist circumference, citing data from a head-to-head trial.

Novo Nordisk A/S’ (NYSE:NVO) executives allegedly ignored internal warnings that the company was unprepared to launch its ...

Novo Nordisk’s new top executive will need to help the company close the gap with ... Zepbound and Eli Lilly's diabetes drug Mounjaro now make up over half of U.S. prescriptions for so ...

Novo Nordisk is banking on fresh leadership to help it reclaim the crown in the booming weight loss drug market. Stream Los Angeles News for free, 24/7, wherever you are. The Danish drugmaker on ...